Aviron FluMist Initial Indication May Exclude Youngest Children, CEO Says
Executive Summary
Aviron is willing to change the proposed pediatric indication for its intranasal flu vaccine FluMist if that would hasten FDA approval, CEO Boyd Clarke told analysts July 30.